Herlin Troels
Arhus Universitetshospital, Skejby, Børneafdelingen, Arhus N.
Ugeskr Laeger. 2008 Jun 9;170(24):2105-8.
In recent years the treatment of juvenile idiopathic arthritis (JIA) has undergone marked changes. There is substantial evidence that inhibitors of tumor necrosis factor alpha (TNFalpha) like etanercept, infliximab and adalimumab show significant efficacy when standard therapy fails, and long-term tolerability is fairly good. Patients with systemic JIA do not respond well to treatment with TNF inhibitors, but they may benefit from treatment with IL-1 and IL-6 receptor antagonists. Our knowledge is still limited regarding which patients respond to a specific biological therapy.
近年来，青少年特发性关节炎（JIA）的治疗发生了显著变化。有大量证据表明，肿瘤坏死因子α（TNFα）抑制剂，如依那西普、英夫利昔单抗和阿达木单抗，在标准治疗失败时显示出显著疗效，且长期耐受性相当良好。全身型JIA患者对TNF抑制剂治疗反应不佳，但他们可能从白细胞介素-1和白细胞介素-6受体拮抗剂治疗中获益。关于哪些患者对特定生物疗法有反应，我们的了解仍然有限。
